OncoMatch/Clinical Trials/NCT01949129
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Is NCT01949129 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments for acute lymphoblastic leukaemia.
Treatment: VP16 · Thiotepa · Treosulfan · Fludarabine · Busulfan · ATG Thymoglobulin · Cyclophosphamide · Grafalon — The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen. The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Disease stage
Required: Stage COMPLETE REMISSION
Prior therapy
Cannot have received: stem cell transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify